Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson

The 2022 bear market might not be over, with some blue-chip economists predicting a further 18% to 43% decline before we bottom. JNJ and ABBV are two defensive healthcare dividend kings, which are up in 2022, helping investors sleep well at night in these turbulent times.

Johnson & Johnson And AbbVie: 2 Great Dividend Aristocrats For What's Coming Next

Merck

Pfizer

The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.

3 Pharma Stocks' Post-Earnings Price Moves

AbbVie stock (NYSE: ABBV) reported its Q2 results last week, with revenue falling short and earnings above the street estimates.

What's Happening With AbbVie Stock?

JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif. , Aug. 3, 2022 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUX™ XC for the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition.

FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition

Big pharma executives are worried that one part of the Inflation Reduction Act will reduce their companies' profits.

Medicare Drug Pricing Changes Could Be Coming: Time to Ditch Pharma Stocks?

AbbVie has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $30.38B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 4.02% yield

Why AbbVie Is A Top 25 Dividend Giant

TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.

Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases

Both Merck and AbbVie reported their Q2 earnings last week, and this article provides a review of their earnings. We like both given their strong pipeline and safe dividends.

Merck And AbbVie Q2: Pipeline And Dividends In Focus

Abbott Labs

PepsiCo

These stocks have reliable dividends and strong underlying businesses.

3 Dividend Aristocrats to Buy in August

T. Rowe Price Group

With the market down close to 20% this year, passive income has become more important.

Earn $300 in Quarterly Retirement Dividends With 3 Easy Steps

AstraZeneca

These stocks share several things in common.

3 Stocks We Think Could Beat the Market in the Second Half of 2022

NEW ORLEANS , July 29, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

ABBVIE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV

The drugmaker's Q2 results aren't sitting well with shareholders today.

Why AbbVie Stock Is Tanking Today

AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales.

AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag

AbbVie Inc. (NYSE:ABBV ) Q2 2022 Results Conference Call July 29, 2022 9:00 AM ET Company Participants Liz Shea - Head, IR Rick Gonzalez - Chairman and CEO Rob Michael - Vice Chairman and President Jeff Stewart - EVP and Chief Commercial Officer Tom Hudson - SVP R&D, and Chief Scientific Officer Carrie Strom - SVP, and President, Global Allergan Aesthetics Neil Gallagher - VP and Chief Medical Officer Roopal Thakkar - Vice President, Global Regulatory Affairs Conference Call Participants Andrew Baum - Citi Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo Gary Nachman - BMO Capital Markets Chris Schott - J.P. Morgan Steve Scala - Cowen Chris Raymond - Piper Sadler Tim Anderson - Wolfe Research Geoff Meacham - Bank of America Colin Bristow - UBS Chris Shibutani - Goldman Sachs David Risinger - SVB Securities Operator Good morning and thank you for standing by.

AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2022 Results - Earnings Call Transcript

AbbVie (NYSE: ABBV ) recently published the company's second-quarter 2022 financial data. The results weren't very different from what Wall Street's analysts had expected.

ABBV Stock Slips as AbbVie Faces Opioid Lawsuits

AbbVie (ABBV) delivered earnings and revenue surprises of 1.81% and 0.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Q2 Earnings Beat Estimates

AbbVie narrowly topped second-quarter expectations Friday and reaffirmed its earnings outlook. But AbbVie stock fell early.

AbbVie Ekes Out Narrow Second-Quarter Beat, Confirms 2022 Outlook

Shares of AbbVie Inc. ABBV, -0.93% were down 1.3% in premarket trading on Friday though the company met earnings and revenue expectations for the second quarter of the year. AbbVie had earnings of $924 million, or 51 cents per share, in the second quarter of this year, compared with $766 million, or 42 cents per share, in the same quarter a year ago.

AbbVie reports an increase in second-quarter revenue, led by sales of Humira

AbbVie Inc has set aside about $2 billion to resolve thousands of lawsuits against its Allergan unit over the marketing of its opioid products, the company said on Friday.

AbbVie sets aside $2 billion to settle U.S. opioid claims

Reports Second-Quarter Diluted EPS of $0.51 on a GAAP Basis, an Increase of 21.4 Percent; Adjusted Diluted EPS of $3.37, an Increase of 11.2 Percent; These Results Include an Unfavorable Impact of $0.14 Per Share related to Acquired IPR&D and Milestones Expense 1  Delivers Second-Quarter Net Revenues of $14.583 Billion, an Increase of 4.5 Percent on a Reported Basis and 6.1 Percent Operationally  Second-Quarter Global Net Revenues from the Immunology Portfolio Were $7.207 Billion, an Increase of 17.8 Percent on a Reported Basis, or 19.2 Percent on an Operational Basis; U.S. Humira Net Revenues Were $4.664 Billion, an Increase of 9.6 Percent; Internationally, Humira Net Revenues Were $699 Million, a Decrease of 13.8 Percent on a Reported Basis, or 7.3 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $1.252 Billion; Global Rinvoq Net Revenues Were $592 Million; Combined Global Skyrizi and Rinvoq Net Revenues Were $1.844 Billion   Second-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.650 Billion, a Decrease of 9.1 Percent on a Reported Basis, or 7.9 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $1.145 Billion, a Decrease of 17.1 Percent, with U.S. Net Revenues of $862 Million and International Profit Sharing of $283 Million; Global Venclexta Net Revenues Were $505 Million   Second-Quarter Global Net Revenues from the Neuroscience Portfolio Were $1.658 Billion, an Increase of 13.7 Percent on a Reported Basis, or 15.2 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $678 Million; Vraylar Net Revenues Were $492 Million   Second-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.371 Billion, a Decrease of 4.4 Percent on a Reported Basis, or 2.1 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $695 Million; Global Juvederm Net Revenues Were $344 Million, Unfavorably Impacted by COVID-19 Restrictions in China and Suspension of Aesthetics Operations in Russia   Confirms 2022 Adjusted Diluted EPS Guidance Range of $13.78 - $13.98, which Includes an Unfavorable Impact of $0.23 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2022 NORTH CHICAGO, Ill., July 29, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2022.

AbbVie Reports Second-Quarter 2022 Financial Results

Scotts Miracle-Gro

Are These Good Long Term Investments Into Cannabis? The post Best Cannabis Stocks To Buy Long Term? 2 To Watch Before August appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Best Cannabis Stocks To Buy Long Term? 2 To Watch Before August

AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?

Should You Buy AbbVie Ahead Of Earnings?

There has been a surplus of buyers for AbbVie shares in 2022, with shares gaining a double-digit 15% and outperforming its Zacks Industry by a fair margin.

AbbVie Q2 Preview: Can Shares Retain Their Strength?

Chevron

Procter & Gamble

Exxon Mobil

A financial advisor can help you understand the advantages and disadvantages of investment properties.

News for AbbVie Stock (ABBV)